Physician profile
Andrew Weissman
NPI 1376675637
$10,301.70
in general payments reported to CMS, 2019-2025
47 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $1,066 · 2021: $1,313 · 2022: $1,315 · 2023: $1,873 · 2024: $1,487 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,948.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,485.55 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,268.68 | 2019-2025 | |
| Amgen INC. | $1,053.90 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $717.70 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.30 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $647.75 | 2019-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $560.72 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $471.76 | 2019-2025 | Farxiga |
| Pfizer INC. | $443.39 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $359.77 | 2019-2022 | |
| Heartflow, INC. | $301.62 | 2022-2025 | |
| Esperion Therapeutics, INC. | $201.73 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $197.33 | 2019-2025 | Lifevest |
| Medtronic, INC. | $189.93 | 2024-2025 | Symplicity G3, Minimed 780g |
| Amarin Pharma, INC. | $183.28 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $144.90 | 2024 | Impella |
| Philips North America LLC | $128.60 | 2023-2025 | Mcot |
| Abbott Laboratories | $101.12 | 2020-2023 | Diamondback Coronary |
| Bayer Healthcare Pharmaceuticals INC. | $98.58 | 2025 | |
| Baxter Healthcare | $95.11 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $87.51 | 2019-2022 | |
| Medicomp INC | $82.60 | 2024-2025 | Telepatch Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $77.46 | 2019-2025 | Amvuttra, Onpattro |
| Portola Pharmaceuticals, LLC | $68.48 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $66.86 | 2019-2021 | |
| Lundbeck LLC | $66.15 | 2020-2021 | |
| Cvrx, INC. | $54.95 | 2024-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $54.69 | 2023-2024 | Inpefa |
| W. L. Gore & Associates, INC. | $38.75 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $37.55 | 2019 | |
| Novo Nordisk INC | $37.42 | 2023 | Ozempic, Rybelsus |
| Bridgebio Pharma, INC. | $32.95 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $31.87 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $31.59 | 2023-2024 | Edarbi, Edarbi |
| Bardy Diagnostics, INC. | $30.00 | 2021 | |
| Chiesi USA, INC. | $27.25 | 2019 | |
| Glaxosmithkline, LLC. | $18.24 | 2024 | Nucala |
| United Therapeutics Corporation | $17.78 | 2025 | Tyvaso |
| Edwards Lifesciences Corporation | $17.44 | 2019 | |
| Atricure, INC. | $16.75 | 2022 | |
| Kyowa Kirin, INC. | $16.45 | 2023 | Crysvita |
| Horizon Therapeutics Plc | $15.27 | 2023 | Krystexxa |
| Kiniksa Pharmaceuticals, LTD. | $14.98 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $14.58 | 2019 | |
| Irhythm Technologies, INC. | $13.49 | 2024 | Zio Monitor, Zio Xt Patch |
| Medtronic Vascular, INC. | $11.99 | 2020 | |
| Allergan, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Weissman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.